COVID-19 UPDATE

Contact

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

SEC Filing Details

Document Details

Form

10-K

Filing Date

Mar 11, 2021

Document Date

Dec 31, 2020

Form Description

Annual report which provides a comprehensive overview of the company for the past year

Filing Group

Annual Filings

Company

BioDelivery Sciences International, Inc.

Issuer

BIODELIVERY SCIENCES INTERNATIONAL INC

Filing Formats

View HTML

Download PDF

Download DOC

Download XLS

XBRL

XBRL Viewer

EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

XML - XBRL INSTANCE DOCUMENT

Recent BDSI News

BioDelivery Sciences Reports Second Quarter 2021 Results August 4, 2021

Total Company Net Revenue of $41.4 Million Driven by BELBUCA ® All-Time High TRx Market Share Strong Profitability with GAAP Net Income of $9.1 Million , or $0.09 per share, EBITDA Margin of 32%, and Non-GAAP Net Income of $12.5 Million , or $0.12 per Share, Drives Operating Cash Generation of $9.2 ...

BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine August 4, 2021

The only FDA-approved, ready-to-use oral solution for the acute treatment of migraine with or without aura in adults First step to building a growth platform in Neurology Patent protection until 2036 RALEIGH, N.C. , Aug. 04, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , ...

BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021 July 22, 2021

RALEIGH, N.C. , July 22, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its second quarter 2021 ...

More news

More events

Stay Connected

Stay up to date on the latest news

Get started now